Brightflow Medical

Executive Summary

Brightflow Medical is a French medical device company founded in 2017 and headquartered in Paris, dedicated to addressing severe right-sided heart failure. The company is developing a durable, minimally invasive, percutaneous blood pump designed to improve quality of life for patients with irreversible right ventricular dysfunction. Right-sided heart failure represents a significant unmet clinical need, with limited therapeutic options beyond medical management or heart transplant. Brightflow's approach aims to fill this gap with a device that can be implanted via catheter, potentially offering a less invasive alternative to current surgical mechanical circulatory support. The company's mission underscores a commitment to innovation in cardiovascular devices, targeting a niche but growing patient population. As a private company with no disclosed funding or revenue, Brightflow is likely in preclinical or early clinical stages, focusing on prototype refinement and initial feasibility studies. The executive summary highlights the company's strategic focus on a specific cardiac condition and its novel device concept, which could position it attractively for future partnerships or investment. The company's progress will depend on successful technical validation, regulatory navigation, and clinical evidence generation.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial initiation40% success
• Q2 2027CE mark submission or breakthrough device designation from FDA30% success
• H1 2027Strategic partnership or funding round50% success